Arcus Biosciences Ends Phase 3 STAR-221 Study

Arcus Biosciences ( (RCUS) ) has provided an announcement.

On December 12, 2025, Arcus Biosciences announced the discontinuation of its Phase 3 STAR-221 study due to futility, as the combination of domvanalimab and zimberelimab with chemotherapy did not improve overall survival compared to nivolumab with chemotherapy in treating advanced gastric and esophageal cancers. The company, in collaboration with Gilead Sciences, will focus on analyzing these results and redirecting its R&D efforts towards casdatifan, a potential best-in-class HIF-2a inhibitor, and other emerging programs, with sufficient funding expected to last until at least the second half of 2028.

The most recent analyst rating on (RCUS) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Arcus Biosciences stock, see the RCUS Stock Forecast page.

Spark’s Take on RCUS Stock

According to Spark, TipRanks’ AI Analyst, RCUS is a Neutral.

Arcus Biosciences’ overall stock score is driven by strong technical momentum and positive corporate events, despite financial challenges. The stock’s bullish trend and successful fundraising efforts are significant positives, while financial performance and valuation remain areas of concern.

To see Spark’s full report on RCUS stock, click here.

More about Arcus Biosciences

Arcus Biosciences is a biopharmaceutical company focused on developing innovative cancer therapies, particularly in the field of immuno-oncology. The company is engaged in creating and advancing a pipeline of therapies aimed at treating various cancers, with a market focus on novel antibody and small molecule drugs.

Average Trading Volume: 1,564,904

Technical Sentiment Signal: Buy

Current Market Cap: $3.14B

Learn more about RCUS stock on TipRanks’ Stock Analysis page.